Fully Automated Plasma Beta-Amyloid Immunoassays Predict Amyloid Pathology Defined by Amyloid PET
https://www.sysmex.co.jp/en/rd/report/220322_01.pdf
Plasma Biomarkers for Classification of AD Pathology by a Fully Automated Immunoassay System (HISCLTM Series) https://www.sysmex.co.jp/en/rd/report/220322_02.pdf
The Evaluation of Plasma Aβ1-40 And Aβ1-42 Immunoassays on The Automated Immunoassay Platform (HISCLTM Series) https://www.sysmex.co.jp/en/rd/report/220322_03.pdf
Reference
It is conceivable that AD is a disease that results in synaptic dysfunction and neuronal cell death due to the tau deposition in neurons triggered by Aβ aggregation on the outside of neurons. These brain changes cause the cognitive impairment and psychological and behavioral symptoms, suggesting that the Aβ aggregation and accumulation inside the brain is caused by AD before the presence of cognitive impairment appears, thus, it is believed that early diagnosis and early intervention is more effective in therapies targeting Aβ. Currently, amyloid PET and the plasma Aβ1-42/Aβ1-40 ratio in cerebrospinal fluid (CSF) are used for detecting amyloid aggregates in the brain, but this puts significant burden on patients in terms of access, costs, and their physical wellbeing.1
1．Aβ, a peptide consisting of amino acid residues, is generated by excision from the amyloid precursor protein. Aβ1-40 consists of 40 residues, is the dominant substance, and does not fluctuate significantly as AD progresses. In contrast, Aβ1-42, which consists of 42 residues, has high aggregability and a reduction in Aβ1-42 is detected from the early stage of AD. There are individual differences in the absolute value of Aβ as well as intra-individual variabilities, therefore,
it has been reported that there is a high correlation between the Aβ1-42/Aβ1-40 ratio in CSF and amyloid PET.
The purpose of this report is to communicate our business activities to our stakeholders. It may or may not include information about Sysmex's products or their research and development, but this is not intended for promotion, advertising or medical advice. The information contained in this report is current as of the date of the announcement but may be subject to change without prior notice.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sysmex Corporation published this content on 22 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 March 2022 06:09:07 UTC.
Sysmex Corp is a Japan-based company principally engaged in the health care business. The Company conducts product development, manufacturing, sales, and service in domestic markets, and some products are developed, manufactured, and sold by subsidiaries. Overseas, the Company conducts the manufacturing and sales of products in the Americas, EMEA, China, and Asia Pacific through other companies. Along with its subsidiaries, the Company is involved in the development, manufacture, sale and service of clinical laboratory equipment, laboratory test drugs and products related to laboratory test.
SYSMEX CORPORATION 
